SINGAPORE, Oct. 25 /PRNewswire/ — Singapore company Novus
Scientific Pte. Ltd today announced that the National University
Hospital (NUH), Singapore has operated on the first patient in its
groundbreaking study: Abdominal Wall Closure After
Lipectomy, TRAM/DIEP Flap – Comparison of
TIGR® Matrix (100% Resorbable) vs Polypropylene
(Permanent) Mesh.This randomized study, involving 86 patients,
received DSRB approval on 9th September 2010. There are plans to
expand this to a multi-centre study involving other hospitals in
Singapore and in the U.S. TIGR® Matrix
Surgical Mesh is the World’s 1st Long-Term Resorbable
Synthetic Mesh, and it received 510(k) clearance from the US
Food and Drug Administration (FDA) in February 2010 for use in
reinforcement of soft tissues where weakness exists.
TIGR® Matrix Surgical Mesh was
launched for sale in the U.S. in June 2010.
“TIGR® Matrix feels soft and
conforms well to the surgical site. If the follow up results are
good, this will be beneficial to many patients undergoing TRAM Flap
procedures, as strong native tissue will replace the mesh over
time. This was not possible with permanent synthetic meshes — we
will be monitoring the patient closely during follow up” –
Dr. Wei Chen Ong (Consultant) & Dr. Jane Lim (Senior
Consultant), Division of Plastic, Reconstructive &
Aesthetic Surgery, National University Hospital, Singapore /
Study Investigators, TIGR® Matrix
Clinical Trial.“We’re pleased to get our 1st
randomized patient included in this study. If the results are
promising, we see a number of other potential applications for
TIGR® Matrix besides TRAM Flap donor
sites; it will be interesting to explore these areas when our
surgeons gain more clinical experience and more st
‘/>”/>
